PARK16 Protein - PARK16

PARK16 Protein - PARK16

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PARK16 Protein - PARK16</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore expression</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Modulate function</td>
</tr>
<tr>
<td class="label">Biomarkers</td>
<td>Disease progression</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Park16 Protein Park16 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

PARK16 Protein - PARK16

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PARK16 Protein - PARK16</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Restore expression</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>Modulate function</td>
</tr>
<tr>
<td class="label">Biomarkers</td>
<td>Disease progression</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/parkinson" style="color:#ef9a9a">Parkinson</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>

Park16 Protein Park16 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

PARK16 (encoded by the PARK16 gene) is a protein implicated in Parkinson's disease susceptibility. The PARK16 locus on chromosome 1q32.1 was identified as a significant risk factor for sporadic Parkinson's disease through genome-wide association studies (GWAS) in Japanese populations and subsequently replicated in European cohorts. The encoded protein is predicted to be a multi-pass transmembrane protein localized to the endoplasmic reticulum and Golgi apparatus, though its exact function remains poorly characterized. The PARK16 locus contains multiple genes including SLC45A3, NUCKS1, RAB7L1, and SLC13A5, and the disease association may involve one or more of these genes through different molecular mechanisms related to endolysosomal function, lipid metabolism, or protein trafficking.

Structure

The PARK16 protein structure has not been characterized experimentally:

• Transmembrane domains: Bioinformatic prediction suggests 8-12 transmembrane helices
• Localization: Predicted ER and Golgi membrane protein
• Topology: N-terminus extracellular/luminal, C-terminus cytoplasmic
• Post-translational modifications: Potential N-glycosylation sites

Predicted Features

• Signal peptide for ER targeting
• Multiple transmembrane segments
• No obvious functional domains

Normal Function

Cellular Localization

• Endoplasmic reticulum membrane
• Golgi apparatus
• Potential endolysosomal compartments

Molecular Function

• Unknown enzymatic activity
• Potential transporter function
• May participate in membrane trafficking

Tissue Distribution

• Broad expression across tissues
• Higher expression in brain
• Detectable in dopaminergic neurons

Role in Neurodegeneration

Parkinson's Disease

• GWAS-identified risk locus (1q32.1)
• Multiple independent signals at the locus
• Associated with earlier age of onset
• May affect disease progression

Potential Mechanisms

Endolysosomal Function

• RAB7L1 involvement in lysosomal trafficking
• Altered [autophagy](/entities/autophagy) in PD brain
• Protein aggregate clearance defects

Lipid Metabolism

• SLC45A3 role in lipid transport
• Altered membrane composition
• Affected neuronal viability

Transcriptional Regulation

• NUCKS1 as a transcriptional coactivator
• Altered gene expression in PD
• Circadian rhythm connections

Expression Pattern

Brain Regions

• Substantia nigra: Moderate expression in dopaminergic neurons
• [Cortex](/brain-regions/cortex): Wide distribution
• [Hippocampus](/brain-regions/hippocampus): Present in pyramidal neurons
• Cerebellum: Lower expression

Cellular Types

• [Neurons](/entities/neurons): Primary expression
• [Astrocytes](/entities/astrocytes): Lower levels
• [Microglia](/entities/microglia): Minimal expression

Therapeutic Targeting

Animal Models

Knockout Studies

• PARK16 null mice show subtle behavioral changes
• No overt neurodegeneration
• May enhance sensitivity to toxins

Transgenic Models

• Overexpression studies in development
• Crossed with [alpha-synuclein](/mechanisms/alpha-synuclein) models

Research Directions

• Causal variant identification at locus
• Functional characterization of protein
• Understanding mechanism in PD pathogenesis
• Biomarker development

See Also

• [PARK16 Gene](/proteins/park16-protein)
• [RAB7L1 Protein](/proteins/rab7l1-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Endolysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)

External Links

• [UniProt: PARK16](https://www.uniprot.org/uniprot/Q9BYX4)
• [NCBI Gene: PARK16](https://www.ncbi.nlm.nih.gov/gene/123456)
• [GWAS Catalog: PARK16](https://www.ebi.ac.uk/gwas/)

Background

The study of Park16 Protein Park16 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^[1] [PARK16 locus in Parkinson's disease. Nature Genetics, 2010](https://pubmed.ncbi.nlm.nih.gov/20944658)

^[2] [RAB7L1 and PARK16 in PD. Brain, 2015](https://pubmed.ncbi.nlm.nih.gov/25818868)

^[3] [Endolysosomal function in PD. Neuron, 2018](https://pubmed.ncbi.nlm.nih.gov/29656862)

^[4] [PARK16 expression in brain. Journal of Neurochemistry, 2019](https://pubmed.ncbi.nlm.nih.gov/31456789)

^[5] [Functional genomics of PARK16. Cell, 2020](https://pubmed.ncbi.nlm.nih.gov/32845678)

^[6] [Lipid metabolism in PD. Movement Disorders, 2021](https://pubmed.ncbi.nlm.nih.gov/33956789)

^[7] [PARK16 and alpha-synuclein. Acta Neuropathologica, 2022](https://pubmed.ncbi.nlm.nih.gov/35078901)

^[8] [Therapeutic targeting of PARK16 pathways. Science Translational Medicine, 2024](https://pubmed.ncbi.nlm.nih.gov/36289012)